Intended for healthcare professionals


Merck to pay $58m in settlement over rofecoxib advertising

BMJ 2008; 336 doi: (Published 29 May 2008) Cite this as: BMJ 2008;336:1208
  1. Fred Charatan
  1. 1Florida

    Merck & Company has agreed to pay $58m (£29m; €37m) to settle allegations that advertising for its analgesic rofecoxib (Vioxx) played down potential health risks.

    The civil settlement ends investigations by 29 US states and the District of Columbia into Merck’s previous advertising practices for the drug. Tom Corbett, attorney general of Pennsylvania, said that the agreement is the largest in a multi-state consumer protection case involving drugs.

    Mr Corbett said that in 1999 Merck had launched “an aggressive and deceptive advertising …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription